March 25, 2022

MEND trial expansion & first patient recruitment

View Report

Cynata CEO Dr Ross Macdonald sits down with Ausbiz to discuss its MEseNchymal coviD-19 (MEND) trial which is investigating the early efficacy of Cynata’s Cymerus MSCs in patients with respiratory failure (from multiple causes) in ICU units across Sydney and Melbourne. 

Watch The Interview Here

November 22, 2021

MST Access Updates Research Coverage on Cynata: “Diabetic foot ulcer trial good to go”, with A$2.76/share valuation.

View Report

View the MST Access Research Update on Cynata Therapeutics

June 11, 2021

MST Access Initiates Research Coverage on Cynata: "Unlocking Stem Cell Therapy Potential"

View Report

View the MST Access Initiation Research Report on Cynata Therapeutics

November 25, 2020

H.C. Wainwright & Co. Company Update: “High-Profile Licensing Deal Underscores Cell Therapy Value; Reiterate Buy”

View Report

View the latest H.C. Wainwright Research Update for Cynata Therapeutics

November 12, 2020

H.C. Wainwright & Co. Company Update: “CYP-004 Phase 3 SCUlpTOR Trial Commences; Reiterate Buy”

View Report

View the latest H.C. Wainwright Research Update for Cynata Therapeutics